GSK2982772   Click here for help

GtoPdb Ligand ID: 9554

Synonyms: compound 5 [PMID: 28151659]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GSK2982772 is a first-in-class clinical candidate RIPK1 inhibitor, with anti-inflammatory potential [1]. X-ray structure of co-crystals shows GSK2982772 in a Type III-like kinase inhibitor position.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 100.21
Molecular weight 377.15
XLogP 2.98
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1n[nH]c(n1)Cc1ccccc1)NC1COc2c(N(C1=O)C)cccc2
Isomeric SMILES O=C(c1n[nH]c(n1)Cc1ccccc1)N[C@H]1COc2c(N(C1=O)C)cccc2
InChI InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1
Immunopharmacology Comments
RIPK1 has been shown to be a critical driver of inflammation of various pathways downstream of the death receptors TNFR1, FasL, and TRAIL, as well as Toll-like receptors. Hence, blocking this pathway has the potential to result in a broad therapeutic benefit for multiple inflammatory diseases.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Clinical candidate in psoriasis.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Clinical candidate in RA.
Ulcerative colitis Disease Ontology: DOID:8577
OMIM: 266600
Orphanet: ORPHA771
Clinical candidate in UC.